Pulmonary Disorders and TPE, Therapeutic plasma exchange, Clinical Pathology - Full Vignette with Ex скачать в хорошем качестве

Pulmonary Disorders and TPE, Therapeutic plasma exchange, Clinical Pathology - Full Vignette with Ex

A 68-year-old man develops progressive shortness of breath, blood-streaked sputum, a new pulmonary infiltrate, and acute kidney dysfunction. Multiple other patients present with varying degrees of pulmonary and renal involvement, some post-transplant or on immunotherapy. How should randomized evidence and clinical features direct the use and prioritization of therapeutic plasma exchange in these complex and diverse ICU scenarios? VIDEO INFO Category: Pulmonary Disorders and TPE, Therapeutic plasma exchange, Clinical Pathology Difficulty: Hard - Advanced level - Challenges experienced practitioners Question Type: Clinical Trials Case Type: Multi Patient Explore more ways to learn on this and other topics by going to https://endlessmedical.academy/auth?h... QUESTION During a single 12-hour admitting shift you must interpret randomized data on therapeutic plasma exchange (TPE) to allocate ICU time and apheresis resources. Patient A (index case): A 68-year-old man presents with progressive dyspnea and new blood-streaked sputum. Temperature 38.0 degreesC, pulse 152/min, blood pressure 129/61 mm Hg, respirations 20/min, oxygen saturation 92% on 2 L/min nasal cannula. Exam shows basal crackles without wheeze; there is no rash or synovitis.... OPTIONS A. For severe ANCA-associated vasculitis with diffuse alveolar hemorrhage (Patient A/B), the PEXIVAS 2x2 factorial trial (seven exchanges within 14 days) showed no significant reduction in death or ESKD with TPE, and a DAH subgroup analysis reported a nonsignificant mortality signal (HR 0.52, wide ... B. In ANCA-associated diffuse alveolar hemorrhage, TPE significantly lowered 1-year mortality in a prespecified subgroup and is recommended as mandatory for all hypoxemic cases, with standard-dose glucocorticoids preferred over reduced-dose regimens. C. For lung transplant antibody-mediated rejection (Patient C), randomized trials demonstrate clear survival benefit from TPE plus IVIG over institutional protocols, whereas ANCA-associated pulmonary hemorrhage remains supported only by observational evidence without randomized trials. D. In eosinophilic granulomatosis with polyangiitis with any hemoptysis (Patient D), high-quality randomized pediatric and adult data support preemptive TPE to prevent respiratory failure even with normal imaging and kidney function. CORRECT ANSWER A. For severe ANCA-associated vasculitis with diffuse alveolar hemorrhage (Patient A/B), the PEXIVAS 2x2 factorial trial (seven exchanges within 14 days) showed no significant reduction in death or ESKD with TPE, and a DAH subgroup analysis reported a nonsignificant mortality signal (HR 0.52, wide 95% CI); thus routine TPE is not supported, while reduced-dose glucocorticoids are reasonable. EXPLANATION The index case presents with severe ANCA-associated vasculitis and diffuse alveolar hemorrhage. The largest randomized trial, PEXIVAS, used a 2x2 factorial design testing plasma exchange versus no exchange and reduced-dose versus standard-dose glucocorticoids. It delivered seven exchanges within 14 days in the TPE arm and found no significant reduction in the composite of death or ESKD. Subsequent analysis focused on patients with diffuse alveolar hemorrhage reported a nonsignificant mortality signal with wide confidence intervals.... Further reading: Links to sources are provided for optional further reading only. The questions and explanations are independently authored and do not reproduce or adapt any specific third-party text or content. --------------------------------------------------- Our cases and questions come from the https://EndlessMedical.Academy quiz engine - multi-model platform. Each question and explanation is forged by consensus between multiple top AI models (i.e. Open AI GPT, Claude, Grok, etc.), with automated web searches for the latest research and verified references. Calculations (e.g. eGFR, dosages) are checked via code execution to eliminate errors, and all references are reviewed by several AIs to minimize hallucinations. Important note: This material is entirely AI-generated and has not been verified by human experts; despite stringent consensus checks, perfect accuracy cannot be guaranteed. Exercise caution - always corroborate the content with trusted references or qualified professionals, and never apply information from this content to patient care or clinical decisions without independent verification. Clinicians already rely on AI and online tools - myself included - so treat this content as an additional focused aid, not a replacement for proper medical education. Visit https://endlessmedical.academy for more AI-supported resources and cases. This material can not be treated as medical advice. May contain errors. ---------------------------------------------------